PKP commonly results in glaucoma

Article

Glaucoma is a serious complication following transplantation, with about 50% of eyes requiring further surgery. According to Justyna Izdebska and colleagues from the Medical University of Warsaw, Poland, trabeculectomy seems to be the most effective surgical treatment.

Glaucoma is a serious complication following transplantation, with about 50% of eyes requiring further surgery. According to Justyna Izdebska and colleagues from the Medical University of Warsaw, Poland, trabeculectomy seems to be the most effective surgical treatment.

The data of 718 patients undergoing penetrating keratoplasty (PKP) in one centre between January 2002 and June 2006, were analysed. Post-keratoplasty glaucoma was defined as an increase of IOP above 21 mmHg lasting for at least three months.

Sixty-five patients (9%) were diagnosed with glaucoma before undergoing PKP. Twenty-one eyes were treated with medical therapy and 44 eyes underwent glaucoma surgery before PKP. A total of 137 patients (19%) who underwent PKP, developed glaucoma postoperatively. Medical therapy failed in 45% of cases necessitating further surgery (trabeculectomy, transscleral cyclophotocoagulation, cyklocrio and shunt procedures).

The authors of this study believe that trabeculectomy is the most appropriate way to treat glaucoma resulting from PK.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.